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1. Introduction  
Over the past decades, skin has become an increasingly interesting target for replacement 
therapies. Easy access plays a pivotal role in its widespread use in this context. Current cell 
culture techniques have optimized in vitro expansion of cells obtained from skin biopsies to be 
assembled in three-dimensional matrices and engineered skin equivalents that are amenable to 
clinical use. A wide range of natural scaffolds and synthetic materials are now available as 
matrices in organotypic skin cultures for skin regeneration (Shevchenko et al., 2010). Patients 
with severe skin loss require large-scale production of composite skin equivalents.  
We developed an improved whole autologous bioengineered skin based on the use of a fibrin 
three-dimensional dermal scaffold in which fibroblasts are embedded (World Patent 
WO/2002/072800) (Figure 1). We provided evidence that this plasma-based dermal equivalent 
adequately supports keratinocyte growth (Meana et al., 1998). Immunohistochemical studies 
over long follow-up periods showed that experimental grafting on immunodeficient mice 
yielded a healthy and mature skin with human architecture that persisted even after several 
epidermal turn-overs (Llames et al., 2004). Permanent skin regeneration requires preservation 
of epidermal cell stemness. The preclinical model fulfils this requirement (Larcher et al., 2007). 
Bioengineered human skin has been successfully employed in a clinical scenario (Figure 1)  
for permanent coverage in the case of extensive burns, necrotizing fascitis, removal of giant 
nevi, and graft-versus-host disease (Llames et al., 2004; 2006; Gómez et al., 2011). Currently, 
the use of bioengineered skin has spread to a wider range of applications such as the 
management of injuries of different aetiology including vascular and diabetic wounds and 
more recently the treatment of wounds associated with genetic rare diseases such as 
epidermolysis bullosa (EB). EB is characterized by skin blistering following minor friction or 
mechanical trauma. The condition varies from limited blisters in the skin to a form involving 
internal epithelial lining. The management of EB is mainly supportive with symptomatic 
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treatment, since currently no cure exists. Nevertheless, EB patients may benefit from the 
treatment with new cell-based therapies. In this context, the EMEA awarded the Orphan 
Drug Designation to a chimerical version of the substitute (orphan designation number 
EU/306/369). Two additional strategies to treat EB, based on the use of bioengineered skin, 
are being explored by our team.  
Our approach to study the physiopathology of the skin evolved also toward disease modeling. 
We have established a skin-humanized mouse model system based on bioengineered human 
skin-engrafted immunodeficient mice (Del Rio et al., 2002b; Llames et al., 2004) (Figure1).  
 
 
 
 
Fig. 1. Human bioengineered skin. Human fibroblasts and keratinocytes isolated  
from a skin biopsy are expanded in vitro. The tissue bioengineered skin equivalent is  
based on a fibrin-based matrix containing live fibroblasts as a dermal component and 
keratinocytes as the epidermal component. This bioengineered human skin has been 
successfully transplanted to patients. The skin-humanized mouse model based on the  
stable engraftment of this setting represents a useful pre-clinical platform to model 
physiopathological process and to test innovative therapeutic protocols. Histopathological 
features of the human bioengineered skin in vitro and after clinical and preclinical 
transplantation. H-E: Hematoxylin-Eosin staining. 
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This chimerical model involves the regeneration of human skin, vascularized and innervated 
by mouse vessels and nerves. This method allows for the generation of a large number of 
engrafted mice containing a significant area of homogeneous single donor-derived human 
skin in a relatively short period of time. We have deconstructed-reconstructed skin disorders 
using skin cells isolated from healthy donor or patient biopsies. Our work included different 
rare human monogenic skin diseases, such as the recessive form of dystrophic Epidermolysis 
Bullosa (RDEB), an inherited mechano-bullous disease (Gache et al., 2004; Spirito et al., 2006), 
the UV-sensitive cancer-prone disease Xeroderma Pigmentosum (XP) (Garcia et al., 2010), 
Pachyonychia Congenita (PC) (Garcia et al., 2011) and the Netherton Syndrome (NS) (Di et al., 
2011), both debilitating skin disorders. With this model, we have succeeded in reverting the 
phenotype employing different gene therapy approaches for ex vivo correction of cells. We 
were also able to generate a skin humanized mouse model of acquired conditions such as 
psoriasis, a common chronic inflammatory disease where the immune component plays a 
pivotal role (Guerrero-Aspizua et al., 2010). Finally, the model also serves to conduct studies in 
normal human skin, both in a physiological or pathological context, to gain insight into a 
process such as wound healing (Escámez et al., 2004, 2008; Martinez-Santamaría et al., 2009 
and unpublished results). These wound healing models also allowed the validation of gene 
and cell therapy approaches to improve impaired wound healing conditions and to favour the 
efficacy of bioengineered skin substitutes in tissue regeneration.  
2. The skin 
Skin is the outermost tissue of the body and the largest organ in terms of both weight and 
surface area. It comprises an area of approximately 1,5-2 m2 for an adult and represents 
about 8% of the body weight. The skin has a very complex structure that consists of many 
components and adnexa including hair follicles, sebaceous glands and sweat glands. The 
main function of skin is to act as a barrier to the surrounding environment dangers. It 
protects the body from friction and impact wounds with its flexibility and toughness. It also 
prevents water loss and regulates body temperature by blood flow and evaporation of 
sweat. Chemicals, bacteria, viruses and ultraviolet light are also prevented from entering the 
body by the skin. Furthermore, skin has a large amount of nerves and nerve endings that 
enable it to act as a sensory organ. When exposed to sunlight, skin can produce vitamin D, a 
critical molecule for calcium metabolism.  
The skin is formed by anatomically, functionally and developmentally distinct tissues: the 
epidermis and the dermis. These layers are composed of different types of cellular elements. 
Hence, they are very different in terms of structure and function. 
2.1 Epidermis 
The epidermis is the outermost component of the skin formed mostly by a particular kind of 
epithelial cells known as keratinocytes. Other epidermis resident cells also include 
melanocytes, Merkel and Langerhans cells, responsible for important specialized functions. 
The epidermis is morphologically divided into different layers or strata. From the bottom 
(innermost), these layers are stratum basale (basal cell layer), stratum spinosum (prickle cell 
layer), stratum granulosum (granular cell layer), stratum lucidum (clear layer) and stratum 
corneum (horny cell layer). Keratinocytes produced in the basal layer, where cell 
proliferation is confined, move upward to the outer surface in a process named as epidermal 
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differentiation. During this turn-over, keratinocytes change their structures and 
physiological functions. One cycle of this turn-over process takes about 28 days. 
The differentiation process involves morphological and biochemical changes with temporal 
and spatial changes in gene expression. Specific proteins are characteristic of the cells at the 
different layers of the skin. Thus, the proliferating basal keratinocytes, which express keratin 5 
(K5) and keratin 14 (K14), adhere to the basal membrane (BM). Basal keratinocytes mature into 
suprabasal keratinocytes. This transition is characterized by loss of contact with the BM, 
proliferation arrest, and downregulation of keratins K5 and K14 accompanied by upregulation 
of keratins K1 and K10. Finally, suprabasal keratinocytes undergo an apoptosis-related process 
called terminal differentiation which results in the formation of a layer of dead cornified cells, 
the stratum corneum. This layer is a main component of the protective skin barrier. The 
terminal differentiation process is accompanied by the expression of marker proteins such as 
transglutaminase, involucrin, fillagrin and loricrin among others. The hair follicles (HFs), 
which together with sweat and sebaceous glands form the epidermal appendages, are formed 
during embryogenesis as outgrowths of the epidermis.  
2.2 Dermis 
The dermis is the living layer that acts as a substrate and a support network for the epidermis. 
The essential dermal cell type is the fibroblast, which is responsible for the production and 
maintenance of the structural elements of skin. These elements, which include collagen and 
elastin, combine with non-fibrous substances such as glycosaminoglycans (GAGs) to form the 
extra-cellular matrix (ECM). The ECM also supports the basement membrane, ensuring the 
integrity of the dermo-epidermal junction (DEJ). Organized tissue renewal depends on the 
ECM. Normally, turnover of collagen is low, but occurs at a higher rate during damage repair. 
The vascular network, which is difficult to replace, is quite critical to skin regeneration. 
Without an adequate blood supply, repair is impaired, and if revascularization cannot be 
achieved, undesirable scar tissue formation is enhanced. Adequate regulation of the 
inflammatory and immunologic responses of the skin also plays a pivotal role in tissue 
regeneration. Imbalanced inflammation may prevent the progression of the regenerative 
(Eming et al., 2007; Pierce, 2001) 
A complex BM composed by specialized proteins serves as an epidermal and dermal 
anchoring structure but also clearly establishes a boundary between epithelial and 
mesenchymal territories. Mutations in the genes coding for the BM proteins (i.e. collagen VII 
or laminin 5) are responsible for rare inherited mechano-bullous diseases.  
2.3 Epidermal stem cells 
Early tracing experiments performed in human and mouse epidermis demonstrated  
that within the basal layer of interfollicular epidermis there was a remarkable proliferative 
heterogeneity. However, these studies did not lead the way to the identification of  
bona fide functional markers for human epidermal stem cells (ESCs). Markers including, 
α6bri/CD71dim, and Lrig1+ were suggested to be useful to enrich for highly clonogenic cells 
(Li et al., 2004; Jensen et al., 2008). However, a criterion established more that 20 years ago, 
based on the in vitro proliferative capacity of keratinocytes remains the most reliable way to 
identify the putative stem cells of human interfollicular epidermis (Barrandon & Green, 
1987). Based on these criterion three populations known as holoclones (clones with high 
clonogenic capacity and very high proliferative potential), meroclones (clones with less 
proliferative potential than holoclones, from committed progenitors or transitory amplifying 
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cells) and paraclones (clones with low proliferative capacity near terminal differentiation) 
were defined. This classification is still valid, and considers the holoclone as strictly derived 
from the human interfollicular epidermal stem cell. Thus, clonogenic assays appear to be the 
best predictors of “stemness”, at least in terms of extensive proliferative capacity of the 
putative interfollicular epidermal stem cells (Barrandon & Green, 1987; Mathor et al., 1996). 
These in vitro studies have demonstrated that either wild type or genetically modified 
cultured human epidermal cell clones named as holoclones, are endowed with an 
extraordinary replicative potential. One controversial point in the field of human epidermal 
stem cells in relation to regenerative medicine, is to establish whether there really is a cell 
subpopulation that has all the attributes of stem cells, or if, conversely, cells with limited 
proliferative capacity (defined as a population of transitory amplifying cells) can be 
programmed or reprogrammed to renew the epidermis in the long term (Li et al., 2004). 
However, neither both the actual proportion and performance, nor dynamics of the human 
epidermal repopulating clones in vivo have been studied in detail as done already with 
human hematopoietic stem cells. Although previous attempts to assess the putative stem 
cell behaviour of single genetically modified human clones (holoclones) in vivo were 
unsuccessful (Mathor et al., 1996), recent advances in organotypic cultures and surgical 
techniques have now made it possible to achive this goal (Larcher et al., 2007).  
Much of the current enthusiasm for the study of human embryonic stem cells (hSC) comes 
from the possible therapeutic use of somatic cells derived from them. While skin biopsies 
are the regular source of keratinocytes and ESCs, recent studies aim at generating 
keratinocytes from human embryonic stem cells. By assessing the sequential expression of 
specific transcription factors, Howard Green and co-workers followed the time- and 
migration-dependent development of the keratinocyte lineage from human embryonic stem 
cells in culture (Green et al., 2003). In a recent study these authors also established 
differences between post-natal keratinocytes and those derived from hSC showing that the 
latter have much lower proliferative potential in culture implying that hES-derived single 
keratinocytes cannot be expanded into mass cultures (Iuchi et al., 2006). They also showed 
that optimization of culture conditions improves the proliferation, but not sufficiently to 
permit their clonal isolation. However, our group, in collaboration with researchers at 
INSERM/UEVE U-861 (France) has recently succeeded in obtaining a homogenous 
population of keratinocytes derived from hSC. Following assembly in a proper scaffold and 
grafting to immunodeficient mice, these keratinocytes retained their ability to regenerate a 
fully differentiated self-renewing epidermis (Guenou et al., 2009). In relation with this issue, 
de-differentiation of adult cells into a pluripotent embryonic stage has been achieved. These 
cells are known as iPS (induced pluripotent stem cells) (Takahashi et al., 2007). While iPS 
cells have been generated from somatic cells, optimization of the process is still underway. 
The obtaining of differentiated cells from iPS or hES is still a major challenge. Recently, iPS 
cells have been obtained from EB patients (Tolar et al., 2011) and it is expected that iPSs 
from other skin diseases will soon be generated. So far, iPS cells differentiation to fully 
functional keratinocytes, as performed with hES, has not been reported. It is, however, a 
matter of further attempts and time to achieve this major goal. 
3. Clinical applications of bioengineered skin 
Skin is the most antigenic tissue in the body and it is refractory to currently known tolerance 
induction regimens. This fact has long precluded the use of allogenic skin grafts for 
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permanent tissue replacement. Allogenic cadaver skin grafts have been shown, however, to 
be of value as temporary skin replacement (i.e. temporary coverage of burn patients). When 
used in this context, a rejection of the epidermal layer of the grafted skin is clinically evident 
within 2-3 weeks post-grafting. Therefore, permanent skin regeneration has only been 
achieved with autologous ESCs transplantation (either as part of split-thickness grafts or of 
bioengineered skin equivalents).  
The introduction of tissue-engineering in therapeutics opened the debate on the idea that 
allogenic skin equivalents are better tolerated by the host than the allogenic split-thickness 
grafts. In fact, allogenic bioengineered skin does not appear to evoke acute clinical rejection 
(Falanga et al., 1998). Instead, a gradual replacement of the allogenic cells by host cells occurs 
(silent rejection). This process is probably triggered by a response of the host immune system 
elicited by HLA-mismatch system (Hohlfeld et al., 2005). During this continuous replacement, 
cytokine release, structural support and provision of a moist wound environment supplied by 
the allogenic skin substitute would explain the improvement in the clinical course of wounds 
treated with allogenic bioengineered skin equivalents. Analysis of donor allogenic cell DNA in 
biopsies of healed wounds after application of a living skin equivalent (Apligraf®), for example, 
have demonstrated one-month persistence of allogenic cells in only a minority of venous ulcer 
patients, and the complete disappearance of these cells by two months post-application 
(Griffiths et al., 2004; Phillips et al., 2002). It is a widely demonstrated fact that allogenic 
keratinocytes do not persist and are progressively substituted by autologous keratinocytes of 
the patient in a process that lasts a few weeks. The fate of allogenic fibroblasts it is less clear. 
Some studies have reported persistence for up to 2.5 years (Otto et al., 1995). Within this context, 
it is now clear that allogenic bioengineered skin equivalents have a role only as temporary 
biological dressings with relevant healing promoting activity. Therefore, allogenic skin substitute 
transplantation is currently used to improve the healing of both acute and chronic wounds, 
including EB lesions (Eisenberg & Llewelyn, 1998; Falabella et al., 2000; Fivenson et al., 2003).  
3.1 Permanent replacement of skin losses 
In the mid seventies, Howard Green and co-workers set up the methods for serial culture 
and large expansions of human epidermal keratinocytes based on the use of a specific 
growth factor cocktail and the presence of lethally irradiated mouse fibroblasts acting as a 
feeder layer (Rheinwald & Green, 1975). Although grafting of pure epithelial sheets has 
helped to save the life of seriously burned patients around the world (Carsin et al., 2000; 
Compton, 1992; O´Connor et al., 1981), the approach showed various drawbacks including 
the fragility of the product, a limited engraftment efficacy, abnormal ultrastructure of the 
dermo-epidermal junction resulting in blistering and contracture leading to poor aesthetic 
clinical outcome (Mommaas et al., 1992; Woodley et al., 1988). Soon it became evident that a 
much more robust skin replacement system was needed. A race to develop and market such 
products started in the 80’s and still continues. As a result, bioengineered skin substitutes 
have emerged as the most carefully studied and proven of the advanced wound 
management technologies. While the initial impetus for their development was to replace 
autograft, allograft, and xenograft in acute skin loss applications, they have found even 
wider application in the treatment of chronic wounds. 
Bioengineered skin substitutes represent artificial alternatives to skin grafts that avoid the 
pain, potential complications and surface limitations of native skin harvesting. They should be 
easy to manipulate, resistant and always available in any quantity needed. In terms of 
function, the ideal skin substitute should mimic the physiology of normal skin, being highly 
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effective in achieving tissue regeneration and wound repair. It should be inexpensive, not 
subject to immune rejection by the host, and should have an extensive shelf-life. Tissue 
engineering of cultured skin substitutes is largely based on the strategy that the following 
three components are important in a bioengineered construct: 1) cell source, 2) tissue-
regeneration-inducing factors, and 3) matrix or scaffold (Langer & Vacanti, 1993). A variety of 
cells, soluble mediators, and biopolymers have been tested in various combinations to 
engineer cultured skin substitutes. As already mentioned, epidermal sheets of cultured 
keratinocytes have been applied to wounds as allografts or autografts. Later, it was shown that 
replacing the connective tissue along with keratinocytes may increase mechanical strength of 
healed wounds and reduce ultimate scarring (Cuono et al., 1987; Desai et al., 1991; Gallico, 
1990) so fibroblasts have been included in some artificial skin substitutes (Hansbrough et al., 
1989; Llames et al., 2004; Meana et al., 1998). Others have used matrix-cultured dermal 
fibroblasts alone as a wound healing device (Marston et al., 2003). Due to difficulties in 
producing and marketing autologous skin equivalents, most current commercial 
bioengineered skin substitutes consist of sheets of a biomaterial matrix containing allogenic 
cells (keratinocytes, fibroblasts or both), which are typically derived from neonatal foreskin, a 
convenient tissue source with the added advantages of a higher content of putative 
keratinocyte stem cells, robust cell growth and metabolic activity, and reduced antigenicity. 
The steps in creating and combining the components of bioengineered skin have been 
comprehensively discussed elsewhere (Boyce and Warden, 2002). Many recent reviews have 
summarized the history and current status of matrices and skin substitutes (Beele, 2002; 
Ehrenreich & Ruszczak, 2006; Hansen et al., 2001; Horch et al., 2005).  
Although an ideal skin substitute has not yet been developed, we have contributed within this 
field with the development of a fibroblast-containing fibrin-based bioengineered skin product 
(WO/2002/072800) that does fulfil many of the clinical requirements. The fibroblast-
containing fibrin-based bioengineered skin was devised by carefully looking at the wound 
healing process. Thus, fibrin was chosen as a matrix suitable to host dermal cells in a 
bioengineered skin equivalent. Fibrin is the primary and temporary wound healing matrix 
allowing blood clotting and migration of both, epithelial and mesenchymal cellular elements 
that, in turn, will repair the damaged tissue. The resistance and flexibility of the fibrin clot are 
ideally suited for grafting manipulations. In fact, acellular commercial fibrin gels have been 
used as carriers for human keratinocyte sheets grown, on top, using the standard Rheinwald & 
Green method. This system, replacing only the epidermal tissue, has been successfully used 
for grafting of burn patients (Pellegrini et al., 1999; Ronfard et al., 2000). 
A major breakthrough was achieved with the demonstration that live human fibroblasts 
embedded in blood cryoprecipitate-derived fibrin gels were able to support human 
keratinocyte growth without the need of a feeder layer (Meana et al., 1998). Although soluble 
growth-stimulatory factors provided either by feeder cells or live human fibroblasts may be 
equivalent, the unique mechanical or nesting anti-differentiating signals attributed to feeder 
cells are somehow replaced by survival signals originated as a consequence of keratinocyte-
fibroblast-fibrin interactions. However, fibrin (fibrinogen) may not be the only relevant factor 
since plasma cryoprecipitate also contains additional factors such as fibronectin or 
thrombospondin that may contribute to keratinocyte adherence and survival. More recently, a 
fibrin-based dermal matrix was obtained from pure plasma allowing the generation of fully 
autologous skin equivalents since keratinocytes, fibroblasts and fibrin may come from the 
same individual (Figure 1) (Llames et al., 2004). A major feature of fibroblast-containing  
fibrin-based scaffolds is that human keratinocytes can be seeded at low densities, decreasing 
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the amount of primary cells needed to generate a graftable skin equivalent. This is in greater 
contrast to collagen-based dermal equivalents such as Apligraf® in which keratinocytes are 
seeded at near confluence densities. Other features of the fibrin-based skin equivalent are its 
low cost and long shelf life. Moreover, the fibrin-based bioengineered skin developed by our 
team has been used successfully, in its autologous version, for permanent skin regeneration in 
different situations such as extensive burns, necrotizing fascitis, removal of giant nevi and 
graft-versus-host disease (Figure 2) (Llames et al., 2004; Llames et al., 2006; Gómez et al., 2011).  
 
 
Fig. 2. Clinical applications of fibrin-based bioengineered skin. (A) Permanent skin 
regeneration on burn patients after autologous transplantation. (B) Skin regeneration on 
chronic ulcers by allogenic temporary coverage. 
The treatment of more than 100 patients with extensive and severe burns, carried out in 
several Spanish hospitals, has achieved reasonable cosmetic results and encouraging graft take 
percentages. Two major causes were disclosed as responsible for cases of poor engraftment: 1) 
resistant infections of the graft recipient bed and 2) poor vascularised wound beds. These 
processes jeopardize the viability of bioengineered skin and are significantly affected by 
wound bed conditioning. Antimicrobial peptides (AMPs) are effective against a broad 
spectrum of pathogens, have low rates of bacterial resistance and in some cases favour the 
repair process. As such, they emerge as an alternative to conventional antibiotics. Concerning 
this issue, our studies support that cutaneous tissue engineering in combination with gene 
therapies may provide a strategy to promote neoangiogenesis (Lasso et al., 2007; Lugo et al., 
2011) and combat infection at the same time (Carretero et al., 2004; Carretero et al., 2008). 
3.2 Temporary dressing for chronic wounds   
The primary difficulties associated with commercial autologous bioengineering skin 
substitutes related to high cost and logistics make them relatively unpopular products on 
the market. However, the use of allogenic skin equivalents for chronic wounds is a different 
story. The treatment of such hard-to-heal, chronic, open wounds has gained importance as 
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both, the aged segment of the population in the industrialized world and the incidence of 
comorbid states, such as diabetes mellitus and atherosclerosis have increased. Thus a 
potential market of 1-2% of the total population in the developed countries led to the 
development of several competing commercial products struggling to show their benefits in 
the clinics (Eisenbud et al., 2004; Herschthal & Kirsner, 2011; Límová M., 2010).  
Although great advances in terms of molecular mechanisms underlying the process of 
wound healing are being achieved, the science behind treatment of chronic wounds with 
skin substitutes is mostly empirical and not well understood. Several beneficial effects range 
from maintenance of a biochemically balanced moist wound environment to structural 
support for tissue regeneration and/or the provision of beneficial cytokines and growth 
factors to the wound bed. The latter is perhaps the best bet as skin substitutes made with 
younger donor cells appear to work better. In fact, Mansbridge et al. have reported that the 
viability and metabolic activity of the cellular component of a skin substitute is essential for 
therapeutic efficacy and have proposed that this is due to the need for ongoing cytokine 
expression in the wound bed following application (Mansbridge et al., 1998). In this regard, 
these authors also showed that metabolic activity, but probably not cell proliferative 
capacity, appears to be the critical event associated with healing efficacy.  
As mentioned, allogenic skin substitutes provide cells that do not persist on the recipient 
site and thus, can be considered safe. In the case of chronic wounds, therefore, the goals of 
skin substitute therapy have evolved away from providing an immediate new skin 
(involving graft take) towards the more reasonable goal of providing a temporary biologic 
dressing that accelerates skin tissue regeneration and wound healing by stimulating the 
recipient's own wound bed-derived skin cells. Defining the specific, discrete causes of the 
healing impairment may thus help to develop a combination of cell and gene therapy 
approaches aimed at providing a la carte solutions for the different subsets of chronic wound 
suffering patients. While the end point of wound closure is the most intensely studied, there 
is also increasing focus upon the quality of the healed wound and in pain control. Cell-based 
wound therapies have indeed the potential to reduce both wound contraction and pain. Of 
note, an allogenic version of the fibroblast-containing fibrin-based skin equivalent has been 
used as an efficient means for triggering/promoting healing at the patient’s own expense 
and releasing pain (Camblor-Santervas et al., 2003; Coto-Segura et al., 2007, 2008). A great 
efficacy/recurrence ratio has been achieved by using this allogenic bioengineered skin as a 
temporary cover. In particular, an 80% healing rate was attained by the weekly application 
of fresh allogenic bioengineered skin during an average period of 6.6 weeks. Relatively high 
percentage of ulcer recurrence (25%) is observed since these temporary substitutes do not 
cure the underlying ischemic or diabetic disease (Llames et al., 2008). As mentioned before, 
cutaneous tissue engineering in combination with gene therapy may provide strategies that 
extend the temporal effects at a local level, for example, by producing VEGF or other pro-
angiogenic factors that enhance angiogenesis during the healing process (Lasso et al., 2007; 
Lugo et al., 2011).  
3.3 Skin bioengineering for Epidermolysis Bullosa  
The skin is the site of a wide variety of inherited diseases. In fact, genes involved in more 
than 80 skin disorders have been identified some of which are causative of rare diseases. 
Low prevalence, less than 1 affected in 2000 individuals, is the common feature shared by all 
rare diseases. Rare diseases are often chronically debilitating or even life-threatening and the 
impact on the quality of life of affected patients (of whom many are children) and their 
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family members is significant. The limited number of patients and scarcity of relevant 
knowledge and expertise conferred on them a remarkable research interest on rare diseases. 
The fact that this low prevalence conditions can serve as models for more common disorders 
and that their study/management frequently require multidisciplinary innovative 
approaches add value to the development of this field. To date, a very limited number of so-
called orphan drugs are marketed, leaving the majority of rare diseases without any 
effective treatment. This fact has focused additional attention on new therapeutic 
approaches such as gene therapy. Cutaneous gene therapy has been one of most intensively 
explored fields (Del Rio et al., 2002a). In fact, the first successful gene therapy trial for 
junctional epidermolysis bullosa (JEB), a rare mechano-bullous genodermatosis, has been 
reported (Mavilio et al., 2006). Mavilio et al. transplanted genetically engineered epidermal 
stem cells from a JEB adult patient affected by laminin beta3-deficiency modified with a 
retroviral vector expressing LAMB3 cDNA. Moreover, long-term correction of RDEB using 
genetically modified human keratinocytes has been also achieved in pre-clinical assays (Del 
Rio et al., 2004; Spirito et al., 2006). Indeed, permanent correction involves vector-mediated 
transgene integration into the target-cell genome. Safety concerns related to insertional 
mutagenesis arose as a consequence of cancer development in two patients undergoing 
hematopoietic gene therapy for an inherited immunodeficiency (Hacein-Bey-Abina et al., 
2003). Therefore, although gene therapy remains the golden standard for genetic disease 
correction, alternative therapeutic strategies such as cell therapy might be effective. On this 
regard, the previously mentioned orphan drug chimerical skin (autologous keratinocytes 
and allogenic fibroblasts) has been proved to be useful for RDEB treatment in the pre-
clinical skin humanized mice as discussed further in this chapter. The attempt to improve 
the healing of EB lesions (including donor sites) by allogenic skin substitute transplantation 
(Eisenberg & Llewelyn, 1998; Falabella et al., 2000; Fivenson et al., 2003) has shown to report 
benefit and need to be explored in a systematic manner.  
3.3.1 Allogenic bioengineered skin  
Mitten deformities of the hands and feet occur in nearly every patient with the most severe 
form of RDEB (RDEB sev gen), and in at least 40–50% of all other RDEB patients. Hand 
deformities include adduction contractures of the first web space, pseudosyndactyly, and 
flexion contractures of the interphalangeal, metacarpophalangeal, and wrist joints. Surgical 
intervention is commonly performed to correct these deformities, but recurrence and the 
need for repeated surgery are common. Life-table analyses emphasize the need for early 
surveillance and intervention, since musculoskeletal complications may occur within the 
first year of life. The severity of the deformity worsens with age, and surgical correction 
becomes more difficult. Standard surgical procedures for the management of hand 
deformities in DEB includes incisional release of contracture and digits follow by autologous 
partial-thickness skin grafts transplantation to cover secondary wounds. Partial-thickness 
skin grafts are taken from patient’s own skin (e.g. the top segment of the leg), thus creating 
an additional open wound (a donor site).  
Figure 3 shows a surgically created donor site during the standard programmed treatment 
for pseudosyndactyly and contracture. The skin obtained from the patient’s donor site 
(Figure 3F) is used to cover the wounds that result from incisional release of contracture and 
digits (Figure 3B-C). In the literature there is no consensus on the management of the split-
thickness donor sites secondary to reconstructive surgery (Demirtas et al., 2010; Pan et al., 
2011). On the other hand, allogenic bioengineered skin transplantation has proven to be of 
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clinical value when used as a healing device aiming at tissue repair/regeneration for chronic 
wounds (Camblor-Santervas et al., 2003; Coto-Segura et al., 2007, 2008; Eisenbud et al., 2004; 
Herschthal & Kirsner, 2011; Límová M., 2010) such as vascular ulcers and for full thickness 
excisional surgical wounds for skin cancer treatment (Donohue et al., 2005; Gohari et al., 
2002). As previously discussed, this strategy provides a temporary biologic dressing that 
accelerates skin tissue regeneration promoting re-epithelialization from patient wound 
edges and release pain. On that basis, we are currently testing the clinical benefits of 
allogenic bioengineered skin transplantation on DEB patient donor sites to reduce pain and 
accelerate healing (Figure 3G-I).  
 
 
Fig. 3. Surgical management of hand contractures and pseudosyndactyly in RDEB.  
(A) Typical pseudosyndactyly and contracture of the thumb and fingers developed by 
RDEB patients. (B) Standard surgical procedure for the correction of these deformities by 
incisional release. (C) Autograft of secondary wounds with split-thickness skin from donor 
site. (D-E) Surgical generation of a donor site on the patient's upper-leg using a dermatome. 
(F) Split-thickness skin from donor site. (G-I) Donor site transplantation using allogenic 
bioengineered skin (panel H). Courtesy of Dr. Mir, Plato Clinic (Barcelona). The clinical 
images have been taken and reproduced with the signed consent of the patient. 
3.3.2 Autologous “revertant” bioengineered skin  
The term somatic revertant mosaicism refers to the occurrence of a natural phenomenon 
involving spontaneous genetic correction of a first pathogenic mutation in a somatic cell 
(Davis & Candotti, 2010). Different molecular mechanisms such as back mutation, intragenic 
crossover, mitotic gene conversion, and/or second-site mutation might underlie the in vivo 
reversion. Somatic mosaicism has also been reported in genodermatoses, including EB. In 
the skin of these patients, revertant mosaicism is manifested as small patches of clinically 
“better than expected” skin surrounded by easily blistering tissue (Jonkman & Pasmooij, 
2009; Pasmooij et al., 2010). The incidence of this phenomenon of genetic reversion, thought 
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to be rare for years, appears to be more common than imagined (Lai-Cheong et al., 2011; 
May, 2011). As a matter of fact, to date the phenomenon of revertant mosaicism has already 
been found in three Spanish RDEB patients. These patients display patches of non-blistering 
unaffected skin (Figure 4A). The clinical reversion on these long-term persistent patches was 
further confirmed by the presence of type VII collagen that was almost absent in the non 
revertant skin (Figure 4B). COL7A1 pathogenic mutations leading to premature termination 
codons caused this blistering condition in all three patients. In one of these patients, a 
second-site mutation, present in revertant keratinocytes, resulted in reading frame 
correction and wild-type type VII collagen expression leading to restoration of skin function 
(Pasmooij et al., 2010).  
Transplantation of autologous “revertant” bioengineered skin may be a tailored EB therapy 
for patients with somatic mosaicism and is currently being explored in our laboratory in 
collaboration with Marcel Jonkman’s team in the Netherlands. The ultimate goal of this 
strategy is the production of sufficient collagen VII from revertant epidermal stem cells to 
ensure adequate and long-term formation of the anchoring fibrils. 
 
 
Fig. 4. Revertant mosaicism in RDEB Spanish patients. (A) Clinical evidence of “revertant” 
skin patches (black dashed lines). (B) Type VII collagen expression detected by 
immunofluorescence shows almost complete absence of labelling at the dermal–epidermal 
junction in mutant skin but bright linear labelling in the revertant samples. White dashed 
line indicates dermal–epidermal junction. Asterisk depict sub-epidermal blistering.  
4. The skin-humanized mouse  
In vivo studies in the skin of human beings are obviously limited by ethical and practical 
constraints. Current knowledge mainly stems from the use of murine models, including 
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knockout and transgenic strategies. However, based on the significant differences existing 
between human and murine skin architecture and physiology, the question remains as to 
how far the results can be extrapolated to the human scenario. As an example, animal 
models such as the two-stage carcinogenesis model in the mouse are valuable tools to 
unravel critical mechanisms of disease, but do not faithfully recapitulate the human illness 
counterpart (Garlick, 2007). Studies in large animals such as pigs, whose skin architecture 
and dynamics resemble that of humans, are an alternative, but troublesome and expensive 
(Sullivan et al., 2001). Skin organotypic cultures represent a valid alternative to native skin 
in vivo studies (Bernerd et al., 2001; Egles et al., 2010; Harrison et al., 2006). However, they 
are restricted, among other constraints, by their short culture life span and the absence or 
faulty pivotal mesenchymal responses such as angiogenesis. To circumvent these problems, 
researchers have often used xenogenic transplantation of donor/patient cutaneous biopsies 
to immunocompromised mice to perform relevant in vivo experimentation in a human 
context. However, in addition to difficulties in sourcing, a major concern for this type of 
experiments is the marked heterogeneity of the graftable skin samples. In fact, differences in 
genetic background, body site or patient’s sun exposure history, among other factors, may 
severely hamper the outcome of the study. A possibility to overcome these drawbacks 
involves the stable regeneration of normal or diseased human skin in appropriate hosts by 
means of tissue engineering (Khavari, 2006). This approach, although realistic, represents a 
significant challenge that involves adequate human epidermal stem cell manipulation in 
vitro, a technique that only a limited number of laboratories can handle. Hence, stable 
engraftment and regeneration of enough human skin for in vivo studies upon grafting of 
skin substitutes to immunodeficient mice need to be standardized. Our group has 
developed a methodology enabling the generation of large numbers of mice engrafted with 
a significant area of single donor-derived human skin. The system, named as the skin-
humanized mouse, is based on the optimized grafting of a fibrin-based bioengineered 
human skin (Del Rio et al., 2002b; Escámez et al., 2004; Llames et al., 2004). Using this 
setting, a mature, quiescent, homogeneous human skin is achieved avoiding the need for 
volunteers and overcoming major differences in tissue architecture and kinetics with mouse 
skin.  
The technical procedure involves the deconstruction-reconstruction of the skin of healthy 
donors or patients suffering from the different diseases (Figure 1). That is, in vitro isolation 
and amplification of cells (fibroblasts and keratinocytes, including the population of 
epidermal stem cells) from biopsies and their assembly as a bioengineered skin that is 
subsequently transplanted to immunodeficient mice (Del Rio et al., 2002b; Llames et al., 
2004) (Figure 5).  
The human regenerated skin showed the restoration of both epidermal and dermal skin 
compartments (Figure 6; Llames et al., 2004) indicating functional epidermal stem-cell 
preservation as further confirmed by the analysis of the regenerated skin after a 
secondary transplant protocol (Larcher et al., 2007). The secondary transplant protocol on 
immunodeficient mice is conducted by purifying epidermal and dermal cells from the 
regenerated skin after primary transplantation. These cells are secondary transplanted to 
immunodeficient mice as part of a human bioengineered skin. Stable regeneration of skin 
displaying a well-stratified and differentiated epithelium 40 weeks post-grafting is 
achieved, which is only possible with epidermal stem cells whose stemness has been 
preserved.  
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Fig. 5. Bioengineered skin orthotopical transplantation procedure. (A) Full thickness 12 
mm circular wounds are created on the dorsum of a 6-week old nude mouse. (B-C) Mouse 
skin is de-vitalized by three frozen and thaw cycles. (D-F) The bioengineered skin is placed 
covering the wound. (G-H) De-vitalized mouse skin is used as a biological bandage and 
held in place by suture. (I) Human and mouse skin boundaries are outlined by a dashed 
line. (J) Immunostaining of human involucrin at the junction of regenerated human skin and 
murine host denoting the human origin of the regenerated epidermis. (K) Immunostaining 
of human vimentin at the junction of regenerated human skin and murine host denoting the 
human origin of the regenerated dermis. 
Moreover, regenerated human skin retains the main physio-pathological characteristics of 
the donor/patient opening a range of possibilities for faithful recreation of different human 
skin pathologies in vivo (Gache et al., 2004; Spirito et al., 2006). The skin-humanized mouse 
model also offers the possibility of using genetically modified human keratinocytes and/or 
fibroblasts. These humanized models have been a unique platform on which to evaluate 
innovative therapeutic strategies in dermatology such as cell therapy using ESCs derived 
from both adult and embryonic stem cells (Escámez et al., 2009; Guenou et al., 2009; Larcher 
et al., 2008; Larcher et al., 2009) and gene therapy (Bergoglio et al., 2007; Del Rio et al., 2002b; 
Di Nunzio et al., 2008; Escámez et al., 2008; Escámez et al., 2004; Larcher et al., 2001; Larcher 
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et al., 2007; Lasso et al., 2007). In this chapter, we summarized our experience with the 
system in modeling various normal and pathologic skin processes. 
 
 
Fig. 6. The skin humanized model recapitulates the main anatomo-pathological features 
of human skin. Presence of a stratified well-differentiated epithelium. (A) Keratin K5 
immunostaining (green) and keratin K10 immunostaining (red) on the regenerated human 
skin. (B) Loricrin immunostaining on the regenerated human skin. (C) Masson’s trichrome 
staining showing a well-vascularized, mature, collagen-rich dermis on the regenerated 
human skin. (D) Laminin immunostaining of the dermo-epidermal junction denoting basal 
membrane restoration on the regenerated human skin. 
4.1 Modeling rare monogenic skin diseases 
The European Commission on Rare Diseases estimated that between 6000 and 8000 different 
rare diseases affect or will affect 29 million people in the European Union. In Spain, around 
3 million people are affected by a rare disease. Poor availability of diagnostic and 
therapeutic options is a major consequence of the limited funding dedicated to research on 
rare diseases. Recently, a great effort is being made by the worldwide scientific community 
to optimize human and financial resources for the study of these diseases. In Spain, as an 
initiative of the Instituto Nacional de Salud Carlos III, the Centre for Biomedical Network 
Research on Rare Diseases (CIBERER), a network structure has been set up to pool and 
promote excellence in research devoted to the diagnosis and therapies of rare diseases. 
Within this picture, development of rare disease models, especially in a human context, 
would contribute to the basic and translational research toward individualized medicine by 
making patients and their families more immediately aware of potential medical 
interventions. Moreover, rare diseases can serve as models for more common diseases and 
the complexity of rare diseases often requires multidisciplinary innovative approaches. 
Based on our solid background in the field of dermatology and our consubstantiation with 
the objectives of CIBERER, our interest in translational research has grown over the years. 
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As a result, we have model a wide range of different rare genodermatosis including 
photosensitive conditions, some of which are described in the present chapter.  
4.1.1 Mechano-Bullous genodermatosis: Recessive Dystrophic Epidermolysis Bullosa 
(RDEB)  
As already mentioned, Epidermolysis Bullosa (EB) comprises a clinically and genetically 
heterogeneous group of rare skin disease characterized by skin blistering, either 
spontaneous or induced by minimal trauma. Based on the level of blister disruption, three 
types of EB are defined: Simplex (EBS), junctional (JEB) and dystrophic (DEB) (Fine et al., 
2008). The prevalence of EB in Europe is estimated to be 0.60 per 10,000 individuals 
(Bruckner-Tuderman, 2008). In Spain the prevalence remains unknown because the genetic 
diagnosis has been recently settled by our team since 2006 with the scientific support of  
 
 
Fig. 7. Schematic diagram of the experimental design for in vivo RDEB keratinocyte 
correction in a humanized mouse model by gene therapy and chimerical bioengineered skin. 
Histological and immunofluorescence staining for Col VII appearance of a (A,B) genetically 
corrected, (C,D) non-corrected and (E,F) chimerical bioengineered EBD engrafted mice. 
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European Diagnosis Reference Centres1 and as part of the CIBERER network (Cuadrado-
Corrales et al., 2010; Escámez et al., 2010; García et al., 2011). Studies carried out by our 
research team in collaboration with Dr. Meneguzzi team showed the possibility of achieving 
a lasting recapitulation of monogenic hereditary skin diseases of different subtypes of EB 
(Del Rio et al., 2004; Gache et al., 2004; Garcia et al., 2007). For instance, the recessive subtype 
of DEB (RDEB; OMIM: 120120), the most severe form of EB, is due to mutations in the gene 
encoding type VII collagen (COL7A1). In particular, null mutations leading to complete 
absence of collagen VII entail physical deformities and increased risk of developing skin 
cancer which reduces their life expectancy dramatically. Extensive blistering of regenerated 
human skin obtained by orthotopic grafting of bioengineered cutaneous equivalents 
containing collagen VII-null RDEB keratinocytes was observed at a histological level, 
similarly to skin biopsies from RDEB patients (Figure 7C-D). Genetic modification of RDEB 
epidermal stem cells by retroviral vectors encoding human collagen type VII used in the 
generation of the skin equivalents (Figure 7A-B) resulted in a complete and permanent 
reversion of this phenotype. Phenothypic correction was also attained by a cell-based 
therapy based on the use of a chimerical bioengineered skin (Figure 7E-F). 
4.1.2 Xeroderma Pigmentosum (XP): A photosensitive condition 
UV radiation is the main noxious and carcinogenic agent for human skin (Brash et al., 1996; 
Kraemer, 1997; Matsumura & Ananthaswamy, 2002; Mudgil et al., 2003; Setlow, 1974). There 
is compelling evidence that each of the three main types of skin cancer, basal cell carcinoma 
(BCC), squamous cell carcinoma (SCC) and melanoma, is caused by sun exposure. As 
commented above, studies of UVB effects on the skin of volunteers are precluded by ethical 
and technical restraints and are inconceivable in cancer-prone patients. Molecular changes 
associated to UVB irradiation have been extensively characterized in vitro in keratinocytes in 
culture (Li et al., 2001; Sesto et al., 2002). Although highly informative, these transcriptional 
profiling and other biochemical analyses are somewhat skewed by the fact that cultured 
keratinocytes represent only a mitotically activated basal cell compartment. The presence of 
differentiated cell layers of the epidermis achieved in 3D organotypic cultures allows for 
more accurate in vitro models to study UV effects. However, the organotypic systems often 
maintain a (hyper) proliferative basal stratum as compared with quiescent native human 
epidermis and only allow for relatively short-term studies. Reliable in vivo studies lack 
behind due to the ethical or practical constraints of using human volunteers or inaccurate 
animal models. We therefore challenged our system to assess whether it was capable of 
adequately responding to UV irradiation. To that end, we examined the effect of one 
biological efficient dose (BED) of UVB light in terms of sunburn cell formation and p53 
induction, two well-described surrogate markers of UV action. As predicted, both effects 
were readily detected after irradiation (Figure 8).  
Moreover, by using Caucasian or African-descent donor keratinocytes we were able to 
confirm the well known modulation of the UVB responses by the degree of skin 
pigmentation (Del Bino et al., 2006; Kobayashi et al., 1998). The model also proved 
satisfactory to test topic photoprotective agents as well as DNA damage repair kinetics after 
UVB irradiation in terms of epidermal hyperplasia and keratin K6 induction (Del Bino et al., 
2004; Lee et al., 2002). Based on those results we have also established a photosensitive 
humanized skin models by grafting bioengineered skin containing Xeroderma 
                                                 
1 Dr. Zambruno (IDI, Italy), Dr. Meneguzzi (INSERM, France) and Dr. Batty (Ninewells Hospital, UK) 
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Pigmentosum (XP) patient cells (Figure 8). Xeroderma Pigmentosum (XP) is an autosomal 
and recessive disorder characterized by a severe deficiency in the most versatile DNA-repair 
mechanism in charge of the removal of bulky DNA adducts including UV-induced 
cyclobutane pyrimidine dimmers (CPDs) and pyrimidine pyrimidone photoproducts (6-
4PPs). The first in vivo evidence of XP keratinocyte deficiency in nucleotide excision repair 
(NER) was obtained after acute UVB irradiation (Garcia et al., 2010). Our model 
recapitulated the findings of CPD persistence as previously described using XP-C 
organotypic skin cultures (Li et al., 2001) (Figure 8) and appears suitable to study chronic 
effects including mutagenesis and carcinogenesis.  
 
 
Fig. 8. Skin humanized mice as a model to study UV responses and carcinogenesis-prone 
inherited cutaneous disorders. (A) Schematic diagram of the experimental design.  
(B) Macroscopic appearance of Caucasian (right) and African (left) descent-derived 
regenerated skins. (C) Histological appearance of a 1 BED irradiated Caucasian and (D) 
African descent derived skin 24 hours after irradiation. (F) CPD immunostaining of 1 BED-
irradiated Caucasian and (G) African human regenerated skin 24 hours after irradiation.  
(E) Histological appearance of a 4 BED irradiated Caucasian- and (H) African descent-
derived skin 24 hours after irradiation. (Arrows indicate sunburn cells). (I) Histological 
appearance of a representative section of a photoprotected (SPF 90), UVB-irradiated (4 BED) 
Caucasian-derived skin 24 hours after irradiation. Note the absence of acanthosis, 
epidermolysis, and sunburn cells. In vivo inability to repair DNA damage (CPD) in XP-C 
regenerated skin. CPD immunostaining of 4 BED-irradiated normal African-derived skin 
(control) section at (J) 2 and (L) 72  hours after irradiation. CPD immunostaining of 4 BED-
irradiated XP-C regenerated skin section at (K) 2 and (M) 72 hours after irradiation. Note the 
persistence of CPD labeled cells in all epidermal strata indicating a DNA damage repair defect.  
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4.1.3 Pachyonychia Congenita (PC) 
Pachyonychia congenita (PC) is a rare autosomal dominant keratin disorder characterized 
by thickened and dystrophic nails as well as painful palmoplantar keratoderma and 
blisters on or near the pressure points of the feet (Leachman et al., 2005; Smith et al., 2006).  
 
 
 
 
 
 
Fig. 9. Clinical and histopathological features of human pachyonychia congenita  
(PC) skin. (A-C) Clinical appearance of engrafted mice. (A) Normal, (B) PC-regenerated 
skin from non-affected (buttocks) area and (C) PC-regenerated skin from affected foot 
sole-derived PC cells on immunodeficient mice. Development of a hyperplastic  
response in normal and pachyonychia congenita (PC)-regenerated human skin after 
tape stripping: Keratin K6 immunoperoxidase staining of (D,F) normal and  
(E,G) involved PC-regenerated skin sections at 72 and 360 hours after tape stripping (TS). 
(H) Constitutive expression of K6 in the foot sole-derived PC graft. (I) Expression of K9, 
which is characteristic and exclusively expressed in the palmoplantar suprabasal 
keratinocytes. 
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PC is caused by dominant-acting mutations in any one of the genes encoding the 
differentiation-specific and stress-inducible keratins, K6a, K6b, K16, or K17 (Smith et al., 
2005; Wilson et al., 2011). The dominant-negative mutations on these keratins lead to 
defective intermediate filament formation responsible for all of the epithelial fragility 
symptoms associated with PC. Mouse models involving the PC-related keratin genes elicit 
only a subset of minor PC-specific epithelial lesions (Chen et al., 2008; Chen & Roop, 2005; 
Wong et al., 2005). Importantly, mouse models of PC are recessive, carrying loss-of-function 
alleles whereas, as mentioned, the human PC mutations are dominant negative (Smith et al., 
2005; Wilson et al., 2011). Within this context, our group has contributed with the 
establishment of two skin-humanized models of PC (Figure 9). First model involves the use 
of bioengineered skin from an uninvolved area of PC patients carrying the same K6a 
mutation, displayed epidermal phenotypic changes consistent with a hyperproliferative 
response. Moreover, the use of keratinocytes from affected skin from another patient 
carrying a different mutation in the same codon of the keratin K6a gene resulted in the 
development of a constitutively expressed, bona fide PC phenotype. Currently we are 
evaluating the amenability of these humanized PC models to genetic intervention similar to 
that recently reported in PC patients (Leachman et al., 2010). 
4.1.4 Netherton Syndrome (NS)  
Netherton syndrome (NS) is a congenital skin disorder caused by mutations in the SPINK5 
gene encoding the lymphoepithelial Kazal-type-related inhibitor (LEKTI) (Bitoun et al., 
2003; Chavanas et al., 2000). It is characterized by defective keratinization, recurrent 
infections, and hypernatremic dehydration with a mortality rate of about 10% in the first 
year of life (Borgoño et al., 2007; Descargues et al., 2006; Ishida-Yamamoto et al., 2005). 
Grafting of human NS bioengineered skin onto immunodeficient mice made it possible to 
recapitulate the characteristic histological features of NS (Di et al., 2011), including 
psoriasiform changes and hypergranulosis with a parakeratotic stratum corneum and 
exfoliated corneocytes (Figure 10B). An ex vivo approach using a lentiviral vector to direct 
SPINK5 expression in keratinocytes resulted in reversal of skin abnormalities (Figure 10A) 
(Di et al., 2011). In this study we found that limited numbers of LEKTI-expressing cells 
mediate valuable beneficial effects likely through paracrine effects. 
4.2 Modeling psoriasis, an inflammatory skin disease 
Inflammatory and autoimmune cutaneous disorders are a major health and social concern 
worldwide. They can be disfiguring and disabling and take a toll in terms of the patient’s 
psychological distress. Skin infiltrating T lymphocytes play a pivotal role in triggering and 
maintaining common chronic inflammatory skin diseases such as psoriasis and atopic 
dermatitis, where an unequivocal deregulation in the Th1/Th2/Th17 balance accounts for 
the pathogenesis. In psoriasis this equilibrium is skewed towards Th1, whereas a Th2 
phenotype is predominant in atopic dermatitis. Th17 cells are more abundant in both 
disorders (Di Cesare et al., 2008). 
Reliable animal models for inflammatory cutaneous pathologies will contribute to the 
comprehensive knowledge of the basic mechanisms underlying the epidermal-immune 
cell interactions and the development of new therapeutic strategies. The adequacy of the 
animal model and its robustness to predict outcome will condition clinical success.  
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Fig. 10. In vivo assessment of Netherton syndrome (NS) keratinocyte correction in a 
humanized mouse model by gene therapy. Schematic diagram of the experimental design 
for the generation of skin-humanized mouse model: Histological appearance of a gene 
corrected (A) and non-corrected (B) NS engrafted mice. 
Several transgenic and knockout animal models gave rise to psoriasis- or atopic 
dermatitis-like phenotypes (Danilenko, 2008; Nestle & Nickoloff, 2005; Schon, 1999; 
Shiohara et al., 2004; Zheng & Zhu, 2005). Although the differences in both architecture 
and function between mouse and human skin impose constraints on these models, 
nonetheless they contribute to elucidate the role of certain molecules in the underlying 
pathological processes. Xenotransplantation models of psoriasis closely mimic human 
disorders and have been used extensively (Gilhar et al., 1997; Nickoloff et al., 1995; 
Wrone-Smith & Nickoloff, 1996). However, the number of grafted mice that can be 
obtained from a single patient has ethical and practical limitations. Within this context, 
the bioengineered-skin humanized mouse model emerges as a powerful tool. One of the 
several potential advantages over other genetically modified or xenotrasplantation animal 
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models is the feasibility of performing studies in a human context on homogeneous and 
large samples. This approach was recently used to generate a bona fide skin-humanized 
mouse model for psoriasis (Figure 11) (Guerrero-Aspizua et al., 2010). Activated specific 
lymphocyte subpopulations from the same patients (autologous approach) re-introduced 
by subcutaneous injection, coupled to tape stripping and the ensuing mild alteration of 
the epidermal barrier, triggered the psoriatic response. We demonstrated that a healthy 
normal human skin regenerated in immunodeficient mice using bioengineering 
technology, might give rise to a psoriasiform phenotype if the appropriate signals are 
present, i.e. a wounding stimulus and the appropriate cytokines produced by specific 
lymphocyte subpopulations (Th1/Th17) obtained from unrelated healthy donors 
(allogeneic approach). These signals play a pivotal role in the formation of the psoriatic 
plaque. This approach has contributed to elucidate the immunopathogenesis of psoriasis. 
Several genetic association studies revealed that a large range of susceptibility factors are 
paramount in the acquisition and/or severity of the disease (Roberson & Bowcock, 2010). 
However, a specific spatiotemporal combination of cytokines/factors can act directly on 
the normal lymphocyte-keratinocyte interacting pathways and produce the disease. 
Furthermore, accessible genetic manipulation of the individual cellular components of the 
bioengineered humanized skin will make it possible to assess the contribution of potential 
susceptibility factors to the pathogenesis of psoriasis using this model. Finally, the 
combined use of these technologies will allow for evaluation of the potential therapeutic 
effectiveness of novel compounds. 
 
 
Fig. 11. The skin humanized model develops a psoriasiform phenotype (A) after cytokine 
injection and tape stripping (TS). (B) Psoriatic phenotypic hallmarks included elongation 
(ERR) and fusion of rete ridges (FRR), parakeratosis (PK), and partial loss of the granular 
layer (LGL). 
4.3 Modeling a physiological process: Wound healing  
Human cutaneous wound healing is a complex process not completely understood 
(Coulombe, 2003; Martin, 1997; Singer & Clark, 1999). Development of chronic ulcers 
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associated to a variety of diseases with a prevalence of 1% in the population are major 
problems of the health care system and carry a high social cost (Ramsey et al., 1999; Stockl et 
al., 2004). Even more importantly, those clinical situations may not only have severe effects 
on life quality but also condition the survival of patients, mainly due to the loss of the 
barrier function of the skin. Despite the absence of effective therapies, palliative treatments 
are available. Effective treatment of chronic ulcers is one of the greatest medical challenges 
(Langer & Rogowski, 2009). Currently around 100 clinical trials designed for this purpose 
are ongoing (Margolis et al., 2004; Senet et al., 2003). Within this context, the search for 
reliable human wound-healing models that allow us to address both mechanistic and 
therapeutic matters is warranted. To this end, our team developed an in vivo wound-healing 
model by creating excision wounds on the skin humanized mouse model that faithfully 
recapitulates all major features of cutaneous wound healing (Figure 12). A careful 
characterization of the healing process by monitoring the expression of various epidermal 
and mesenchymal markers showed that re-epithelialization, dermal matrix remodeling and 
basal membrane reorganization accurately mimic the process in humans (Escámez et al., 
2004). This model also allows for the use of in vitro genetically manipulated human 
keratinocytes and/or fibroblasts during the amplification procedure, either to overexpress 
or silence specific genes, generating transgenic or KO humanized-skin respectively.  
A central aim of regenerative medicine is to optimize healing and improve cosmetic 
outcome. In this sense, one of the main challenges is to create smart bioengineered products 
that can deliver growth factors and/or cytokines in a time-controlled fashion, promoting 
scar-free regeneration of embryonic or fetal skin. The combination of cell- and genetic-based 
therapy has made it possible to evaluate the promoting or detrimental wound-healing 
activities of specific factors using different model systems, such as transgenic mice, KO-mice 
or xenograft models (Davidson, 2001; Demarchez et al., 1986; Werner & Grose, 2003). As a 
proof of concept, we selected KGF, a well-characterized factor that is differentially regulated 
in normal and impaired healing, to compare the efficacy of different transient gene transfer 
strategies aimed at delivering smart factors to promote cutaneous repair in the wound 
healing skin-humanized model (Escámez et al., 2008). In the first approach, hKGF was 
delivered to wounds by intradermal injection of an adenoviral suspension. Although wound 
acceleration was achieved, the effect of hKGF was unreliable both in terms of the number of 
successfully targeted animals (versus the total number of treated animals) and re-
epithelialization efficiency. In the second approach, KGF-encoding adenoviral vectors were 
immobilized in a fibrin gel carrier and applied immediately after wounding. In this case, the 
proportion of successfully targeted animals was higher than that achieved with the 
adenoviral injection method, and wound closure rose significantly. A third strategy was 
explored consisting in delivering hKGF protein from ex vivo adenoviral transduced 
fibroblasts that were, in turn, embedded in a fibrin matrix and used to treat the wound. In 
contrast to the two previous methods based on direct adenovirus delivery, this cell-
mediated system did not depend on in vivo cell transduction. This method depends on the 
direct transfer of exogenous KGF therapeutic protein from gene targeted fibroblasts that 
was, in fact, achieved in all treated wounds, leading to a significant improvement in wound 
closure. Although all delivery systems achieved KGF protein overproduction at the wound 
site, with a concomitant re-epithelialization enhancement, only the use of genetically 
modified fibroblast-containing matrix as an in situ protein bioreactor was highly 
reproducible. This method appears the most reliable means to deliver growth factors to 
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wounds avoiding the potential danger of scoring cases of faulty administration as 
therapeutic failures and direct exposure to viral vectors. The bioengineered skin humanized 
mouse model of wound healing emerges as a unique platform for evaluating 
pharmacological, cell and gene therapy strategies for wound healing (Davidson, 2008).  
 
 
Fig. 12. The skin humanized model truly recreates the human wound healing process.  
(A-C) Clinical  and (D-F) histological features of the healing process of a wound until 
complete closure. (A) Non-wounded regenerated skin showing a multilayered human 
epithelium easily distinguish from the mouse epithelium. (D) Differences in the collagen 
deposition are also observed. (B) 1 day-wound plugged with a fibrin-rich clot (FC) (F) 
gradually populated by endothelial cells and fibroblasts (granulation tissue: GT) that by 
remodeling generates a mature dermis (MD) as observed on the older areas of a 7day 
wound. The epithelial tongue observed in (E) migrates along the time until completely cover 
the damaged area by a neoepithelium. 
Diabetes is a systemic disorder with a high and continuously increasing incidence, affecting 
approximately 4% of the world population in developed countries. This index increases in 
relation to current lifestyle (Ramsey et al., 1999; Wild et al., 2004). Despite recent advances in 
the diagnosis and treatment of diabetes, its complications still represent a challenge for 
public health, since approximately 15% of diabetic patients develop a lower extremity ulcer 
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during the course of their illness. In fact, over 25% of hospital admissions of diabetic 
patients are connected to problems with ulcers, particularly on the feet, which if not 
properly treated will result in the amputation of the affected limb (Moulik et al., 2003; 
Widatalla et al., 2009; Wu & Armstrong, 2005). Employing the widely used model of 
diabetes impaired-wound healing, i.e. leptin-deficient ob/ob mice, we examined the repair-
promoting activities of the pleiotropic factor LL-37 antimicrobial peptide. This peptide has 
been shown to play a role in defense and favour repair as previously mentioned. We used 
adenoviral-mediated gene transfer to overexpress this factor around wound margins of full-
thickness wounds generated in this animal model. We showed that LL-37 enhanced the re-
epithelialization rate and granulation tissue formation in a healing-impaired context 
(Carretero et al., 2008). Although this and other animal models have been extensively useful 
in diabetes research (Frank et al., 2000; Michaels et al., 2007), the need to design appropriate 
models in a humanized context has become mandatory as previously discussed. To this end, 
our studies are mainly devoted to develop a humanized animal model of impaired wound 
healing (Martínez-Santamaría et al., 2009 and unpublished results).  
5. Conclusion  
Skin bioengineering has become a bright star in the field of regenerative medicine. The 
original feeble sheet of keratinocytes developed by Green and coworkers (Gallico et al., 
1984) driven by the urgent need to cover a severe burn patient in the mid eighties has 
evolved into complex tridimensional products combining epithelial and mesenchymal cells 
together with a variety of matrices and scaffold materials. The spectrum of applications has 
also grown remarkably counting not only big skin losses (e.g. severe buns) but also various 
forms of chronic wounds including those of genetic origin. Recently, skin bioengineering 
has met gene therapy (Mavilio et al., 2006) and that couple is here to stay as new combined 
therapy protocols are foreseen not only with genetically manipulated keratinocytes but also 
with revertant, spontaneously corrected cells.  
Major challenges remain. At the experimental level, human skin bioengineering has allowed 
the development of faithful skin disease models amenable to the screening of therapeutic 
approaches and mechanistic studies. Some but not all of the skin functions can be restored 
with existing autologous skin substitutes. In fact, bioengineered constructs offering the 
complete regeneration of functional skin, including all the skin appendages (hair follicles, 
sweat glands and sensory organs) are still awaiting development. Establishment of a 
functional vascular and nerve network and scar-free integration of current bioengineered 
products with the surrounding host tissue has neither fully achieved. New basic knowledge 
about epidermal stem cells and their interaction with neighboring mesenchyma will be a key 
to developing new enhanced tissue-engineered skin substitutes. We certainly cannot leave iPS 
cells out of any regenerative medicine equation. Attainable and safe production of genetically 
stable, truly iPS cells together with reliable procedures to obtain specific differentiated cell 
lineages, including epidermis, is conceivable and a door to an unlimited source of autologous 
cells. A smart combination of all these new advances to come hold the promise to fulfill the 
dream of perfect skin regeneration through off-the-shelf, next generation skin bioengineering. 
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